For research use only
| Cat No. | ABC-TC0019 |
| Product Type | Human Kidney Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Adenocarinoma |
| Product Code | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT |
786-O cell line from AcceGen, derived from human renal clear cell carcinoma, applied in cancer biology, tumorigenesis, and drug screening applications.
786-O is a human renal clear cell carcinoma (ccRCC) cell line established from a primary tumor of a 58-year-old male patient. Cells show epithelial, globular morphology with microvilli and desmosomes, and grow anchorage-independently in soft agar. They express parathyroid hormone-related peptide (PTHrP) identical to that produced by breast and lung cancer lines. Cytogenetic and transcriptomic analyses reveal frequent chromosome 3p deletions and HIF stabilization characteristic of ccRCC. A 2023 study reported that reintroduction of a VHL variant (L169P) into 786‑O restored hypoxia regulation and suppressed proliferation in vitro and in vivo. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | 786-o; 786O; 786-0; 786.O; 786-O RCC; RCC 786-O; RCC_7860; RCC 7860; 7860; 786-0WT |
| Species | Human |
| Cat.No | ABC-TC0019 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Kidney |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Kidney Cancer Cell Lines |
786-O cells are a standard model for investigating VHL/HIF-driven oncogenesis, hypoxia signaling, and paraneoplastic syndromes such as hypercalcemia via PTHrP. PTHrP secretion makes them ideal for studying RCC-induced osteolysis and metastatic bone microenvironments. Their ability to grow in 3D assays also supports drug penetration and microenvironment interaction studies relevant to RCC therapeutics.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
